Kiromic Announces Identification of Novel Targets for Allogeneic CAR Gamma Delta T-cell Therapy in Solid Tumors Utilizing Kiromic’s Proprietary Artificial Intelligence Engine

Kiromic Biopharma, Inc. (Nasdaq: KRBP) is an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics.

Kiromic is pleased to announce the identification of new targets for the treatment of solid tumors, identified through the application of its bioinformatics platform (CancerDiff and Diamond AI). These new targets include novel epitopes of NY-ESO-1 and a Cancer Selective Isoform Splice Variant of Mesothelin (Isomesothelin). Strikingly, in vitro, and in vivo experiments have demonstrated that the identified IsoMesothelin variant is an excellent target for specific and potent allogeneic CAR Gamma Delta T-cell therapy for solid tumors.

These preclinical results represent a key milestone in the development process of Kiromic and were showcased in 3 posters presented during the annual April 2021 American Association of Cancer Research meeting:

AACR Posters: 247		Identification of an Ovarian Cancer Selective Splice Variant of Mesothelin Utilizing the Kiromic Proprietary Search Engine CancerDiff
1534		Mesothelin Isoform 2 is a Novel Target for Allogeneic CAR Gamma Delta T-cell Therapy in Solid Tumors
243		Identification of Novel Epitopes of NY-ESO-1 for Solid Malignancies by Kiromic Proprietary Search Engine Diamond

Poster 247: Showcases how CancerDiff was validated and then used to predict the upregulation of IsoMSLN in ovarian cancer.

Technical Capabilities	CancerDiff was able to: -- identify and validate a unique peptide isoform of mesothelin post transcription within 71% of ovarian cancer (OV) specimens, and -- confirmed the upregulation of IsoMSLN in Ovarian cancer.
What makes CancerDiff Special vs. nearest competition	These data sets derived from publicly available proteomic repositories were searched for their unique signature peptide variants that were expressed on the surface of cancer cells.